Celsius Therapeutics

AbbVie Expands IBD Drug Pipeline Again With $250M Celsius Therapeutics Acquisition

AbbVie has acquired Celsius Therapeutics, a startup whose lead program is in early clinical development for inflammatory bowel disease. It’s the latest in a series of AbbVie business deals that broaden the pharma company’s scope in the gastrointestinal condition.

By Frank Vinluan

Celsius Therapeutics heats up with $83M and an IBD drug on path to the clinic

Single-cell analysis biotech Celsius Therapeutics has raised $83 million to advance its pipeline of drugs for autoimmune disorders and cancer. The startup’s lead autoimmune program, a TREM1-blocking antibody for inflammatory bowel disease, is expected to begin human testing in early 2023.

By Frank Vinluan

Health IT

Reducing Clinical and Staff Burnout with AI Automation

As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.

By Dr. Michael Blackman, Chief Medical Officer at Greenway Health

Health IT

Transforming Patient Care: The Role of AI-Powered Assistants

The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.

By IT Medical

Consumer / Employer

Health Executives on Digital Transformation in Healthcare

Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.

By MedCity News

Consumer / Employer

Health Executives on Digital Transformation in Healthcare

Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.

By MedCity News